Takeda Pharmaceutical Stock Quote TAK - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

13.155

Bid

Ask

Volume

438,047

13.08 Day's Range 13.195

0.00 52 Week Range 0.00

Market Cap

78.086B

Previous Close

13.08

Open

13.10

Last Trade

200

13.155

Last Trade Time

12:47:37

Financial Volume

$ 5,764,399

VWAP

13.1593

Average Volume (3m)

Shares Outstanding

1,582,296,000

Dividend Yield

PE Ratio

0.25

Earnings Per Share (EPS)

200.35

Revenue

4.05T

Net Profit

317.02B

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geogr... Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Diversified

Website

www.takeda.co.jp

Headquarters

Chuo, Tokyo, Jpn

Founded

1984

Takeda Pharmaceutical Company Ltd is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker TAK. The last closing price for Takeda Pharmaceutical was $13.08. Over the last year, Takeda Pharmaceutical shares have traded in a share price range of $ 0.00 to $ 0.00.

Takeda Pharmaceutical currently has 1,582,296,000 shares outstanding. The market capitalization of Takeda Pharmaceutical is $78.09 billion. Takeda Pharmaceutical has a price to earnings ratio (PE ratio) of 0.25.

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion...

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder PR Newswire SAN DIEGO, April 23, 2024 SAVITRI™ Study Met Primary Endpoint with...

Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs

Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs PR Newswire TOKYO, April 22, 2024 TOKYO...

U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

− ENTYVIO is Now Available in the U.S. in Both IV and Subcutaneous Administrations for Maintenance Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease...

Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food

FY23 Investment Brings Program Total to Nearly $55 Million, Welcoming Eight New Grant Partners Company Continues to Advance Equity in Under-Resourced Communities with a Focus on Nutrition and...

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic Symptoms ADZYNMA (apadamtase alfa /cinaxadamtase alfa) is the First and Only...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
SYTSYLA Technologies Company Ltd	$ 3.8699 (165.06%)	9.29M
CTMXCytomX Therapeutics Inc	$ 4.195 (157.36%)	151.95M
IMCCIM Cannabis Corporation	$ 1.1723 (36.31%)	37.34M
PBMPsyence Biomedical Ltd	$ 1.1901 (32.32%)	2.59M
CYCCCyclacel Pharmaceuticals Inc	$ 2.7699 (30.66%)	4.66M
CETXCemtrex Inc	$ 0.309 (-72.89%)	14.74M
CVRXCVRx Inc	$ 9.75 (-37.14%)	1.06M
CGCCanopy Growth Corporation	$ 10.61 (-28.70%)	39.84M
BENFBeneficient	$ 2.43 (-26.81%)	144.53k
GVVisionary Holdings Inc	$ 0.1901 (-25.74%)	664.82k
AKANAkanda Corporation	$ 0.115 (23.66%)	166.02M
CTMXCytomX Therapeutics Inc	$ 4.195 (157.36%)	151.95M
SQQQProShares UltraPro Short QQQ	$ 12.21 (2.18%)	82.72M
TLRYTilray Brands Inc	$ 2.005 (-18.83%)	70.14M
AMDAdvanced Micro Devices Inc	$ 143.4053 (-9.45%)	53.34M